Remove Biosimilars Remove Diabetes Remove Hospitals
article thumbnail

Towards a healthier, more equitable and innovative Indian healthcare sector

Express Pharma

Establishing Centers of Excellence and leveraging artificial intelligence for pharma research can advance India’s capabilities in NCEs, biologics, and biosimilars, placing it at the forefront of global pharma innovation. Enable global competitiveness The MedTech sector aspires to reduce import dependence and become globally competitive.

article thumbnail

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Pharmacy Times

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

26
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Evaluation of a Pharmacy-Delivered Oncofertility Intervention

Pharmacy Times

Related Videos Related Content Advertisement June 11th 2025 Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2.

26
article thumbnail

Insights+ Key Biosimilars Events of January 2023

PharmaShots

Ximluci is expected to be available in the UK in 2023 The approval for Ximluci was granted through the EC decision reliance procedure, whereby the MHRA’s decision was based on the EC Ximluci was approved in the UK for wet AMD, DME, diabetic retinopathy, RVO, and visual impairment due to choroidal neovascularization in adults.

article thumbnail

Collaborative Management of Severe Pericarditis: The Role of Pharmacists in Rilonacept Treatment

Pharmacy Times

The medical team, in collaboration with pharmacists, opted to use rilonacept and worked to expedite its delivery to the patient upon hospital discharge. What we did was we admitted him to the hospital. " But that's not such a wise thing, and I believe he was 85 years old, so we decided to admit him.

26
article thumbnail

Fresenius Kabi introduces Vasopressin Injection, USP, in US

Pharma Leaders

Fresenius has invested nearly $1bn for the manufacture as well as distribution of Vasopressin to serve hospitals and health systems in the US. Patients may also suffer from reversible diabetes insipidus after stopping treatment with vasopressin.

article thumbnail

Fresenius Kabi introduces Vasopressin Injection, USP, in US

Pharmaceutical Business Review

Fresenius has invested nearly $1bn for the manufacture as well as distribution of Vasopressin to serve hospitals and health systems in the US. Patients may also suffer from reversible diabetes insipidus after stopping treatment with vasopressin.